What is SIGA Technologies?
SIGA Technologies, Inc. operates as a specialized pharmaceutical entity dedicated to the research, development, and commercialization of medical countermeasures for biothreats and emerging infectious diseases. The company is best known for its flagship product, TPOXX, an orally administered antiviral medication designed to treat orthopoxvirus infections. By addressing significant unmet medical needs, SIGA serves as a vital partner to government agencies and global health organizations, positioning itself as a leader in the biosecurity and pandemic preparedness ecosystem. Their operational model integrates advanced clinical research with strategic manufacturing capabilities to ensure the availability of life-saving treatments in high-risk environments.
How much funding has SIGA Technologies raised?
SIGA Technologies has raised a total of $12.5M across 1 funding round:
Stock Offering
$12.5M
Stock Issuance/Offering (1997): $12.5M, investors not publicly disclosed
Key Investors in SIGA Technologies
Undisclosed Institutional Investor
An undisclosed institutional entity providing strategic capital to support the development of critical biodefense medical countermeasures.
Undisclosed Private Equity Firm
A private equity firm specializing in long-term growth investments within the pharmaceutical and biotechnology sectors.
Undisclosed Strategic Partner
A strategic partner focused on the advancement of antiviral drug development and public health security initiatives.
What's next for SIGA Technologies?
With the backing of $12.5M, SIGA Technologies is well-positioned to scale its commercialization efforts and expand its therapeutic portfolio. The current enterprise-level funding context suggests a strategic pivot toward broadening the application of its antiviral platform beyond existing orthopoxvirus treatments. Future growth will likely be driven by the continued procurement of TPOXX by national health authorities and the acceleration of R&D initiatives targeting other high-priority pathogens. As the global landscape for infectious disease management evolves, SIGA remains focused on leveraging its core competencies to secure long-term stability and enhance its role as a cornerstone of national biodefense infrastructure.
See full SIGA Technologies company page
